1. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
   Luis de la Cruz-Merino et al, 2017, J Transl Med CrossRef
2. Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
   Jasmine H. Francis et al, 2017, Ophthalmology CrossRef
3. Mechanisms of macular edema: Beyond the surface
   Alejandra Daruich et al, 2017, Progress in Retinal and Eye Research CrossRef
4. Wild chrysanthemum extract prevents UVB radiation-induced acute cell death and photoaging.
   Sujiao Sun et al, 2016, Cytotechnology CrossRef
5. Ocular toxicities of MEK inhibitors and other targeted therapies.
   N Stjepanovic et al, 2016, Ann Oncol CrossRef
6. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
   U Urner-Bloch et al, 2016, Eur J Cancer CrossRef
7. Diagnostic and Therapeutic Challenges.
   Céline Faure et al, 2016, Retina CrossRef
8. Exudative retinal detachment.
   Radgonde Amer et al, 2017, Surv Ophthalmol CrossRef
9. [Multifocal serous chorioretinopathy secondary to the use of MEK inhibitors: Illustration and example of management through two case reports].
   A Coutu et al, 2016, J Fr Ophtalmol CrossRef
10. [Serous retinopathy: an important adverse event in tumor treatment].
    I Lüdeke et al, 2017, Ophthalmologe CrossRef
11. Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors
    Andrew Smith et al, 2018, Journal of Ocular Pharmacology and Therapeutics CrossRef
12. New features in MEK retinopathy
    Pallavi Tyagi et al, 2018, BMC Ophthalmol CrossRef
13. Cobimetinib‑/Vemurafenib-assoziierte bilaterale seröse Retinopathie: ein Fallbericht
    Gregor Kastl, 2018, Ophthalmologe CrossRef
14. Involvement of NYD-SP15 in growth and oxidative-stress responses of ARPE-19.
    Yidan Xu et al, 2018, J Cell Biochem CrossRef
15. Oral Selumetinib Does Not Negatively Impact Photoreceptor Survival in Murine Experimental Retinal Detachment
    Colleen M. Cebulla et al, 2019, Invest. Ophthalmol. Vis. Sci. CrossRef
16. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA
    Akosua A. Nti et al, 2019, Retina CrossRef
17. Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
    Sara Touhami et al, 2019, Progress in Retinal and Eye Research CrossRef
18. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
    Silvia Méndez-Martínez et al, 2019, Retina CrossRef
19. Inhaled gold nanoparticles cause cerebral edema and upregulate endothelial aquaporin 1 expression, involving caveolin 1 dependent repression of extracellular regulated protein kinase activity
    Ching-Yi Chen et al, 2019, Part Fibre Toxicol CrossRef
20. Wide field retinal imaging and the detection of drug associated retinal toxicity
    Giulia Corradetti et al, 2019, Int J Retin Vitr CrossRef
21. Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus
    Grace Egan et al, 2020, Journal of Pediatric Hematology/Oncology CrossRef
22. Ultraviolet B Downregulated Aquaporin 1 Expression via the MEK/ERK pathway in the Dermal Fibroblasts
    Won-Oh Kim et al, 2020, Ann Dermatol CrossRef
23. 5-Hydroxymethyl-Furfural and Structurally Related Compounds Block the Ion Conductance in Human Aquaporin-1 Channels and Slow Cancer Cell Migration and Invasion
    Pak Hin Chow et al, 2020, Mol Pharmacol CrossRef
24. Malignant melanoma with retinal detachment due to combination therapy of dabrafenib and trametinib : A case report
    Arisa KISHI et al, 2020, Skin Cancer CrossRef
25. LYTAK1 attenuates proliferation of retinal pigment epithelial cells through TGF‑β‑mediated epithelial‑mesenchymal transition via the ERK/AKT signaling pathway
    Zhen Chen et al, 2017, Exp Ther Med CrossRef
26. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
    Andrew E. C. Booth et al, 2020, Ther Adv Med Oncol CrossRef
27. Detrimental Effects of UVB on Retinal Pigment Epithelial Cells and Its Role in Age-Related Macular Degeneration
    Camille Keisha Mahendra et al, 2020, Oxidative Medicine and Cellular Longevity CrossRef
28. Choriocapillaris Assessment In Patients Under Mek-Inhibitor Therapy For Cutaneous Melanoma: An Optical Coherence Tomography Angiography Study
    Giuseppe Fasolino et al, 2021, Seminars in Ophthalmology CrossRef
29. Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib
    Ana Ursula Gavric et al, 2018 CrossRef
30. Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients
    Sascha Mathias Jung et al, 2021, Klin Monbl Augenheilkd CrossRef
31. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor
    Margot A. Lazow et al, 2021 CrossRef
32. Fibroblast Growth Factor Receptor Inhibitor–Associated Multifocal Serous Retinal Detachments: A Case Report
    Diana H. Kim et al, 2021, Journal of VitreoRetinal Diseases CrossRef
33. Retinal toxicities of Systemic Anticancer Drugs
    Supriya Arora et al, 2021, Survey of Ophthalmology CrossRef
34. Friends or Foes? An Update on Retinal Toxicities of Systemic Medications
    Rui Zhang et al, 2021, Ophthalmic Surg Lasers Imaging Retina CrossRef
35. Bilateral Serous Retinal Detachment Associated with a Mitogen-activated Protein KinaseKinase Inhibitor in a Patient with BRAF-mutant Colorectal Cancer.
    Miho Sakumura et al, 2022, Intern Med CrossRef
36. null
    Heather G Mack et al, 2021 CrossRef
37. Toxicité oculaire des thérapies ciblées anti-MEK et anti-BRAF dans le traitement des mélanomes cutanés métastatiques
    E. Fauviaux et al, 2022, Journal Français d'Ophtalmologie CrossRef
38. Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis
    Carlos Alves et al, 2017, Ophthalmic Res CrossRef
39. Age-Related Changes in Male Skin: Quantitative Evaluation of One Hundred and Fifty Male Subjects
    S. Luebberding et al, 2014, Skin Pharmacol Physiol CrossRef
40. Ocular Inflammatory Complications of Treatment for Metastatic Melanoma
    Andrew M Philip et al, 2022, Ocular Immunology and Inflammation CrossRef
41. Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma During Treatment with Pemigatinib: A Case Report
    Masanobu Yukutake et al, 2022, Intern. Med. CrossRef
42. ACUTE EXUDATIVE POLYMORPHOUS VITELLIFORM MACULOPATHY ASSOCIATED WITH PRIMARY EPSTEIN–BARR VIRUS INFECTION
    Anna M. Lentzsch et al, 2022 CrossRef
43. Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies
    Giulio Barteselli et al, 2022, Drug Saf CrossRef
44. Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study
    Giuseppe Fasolino et al, 2023, JCM CrossRef
45. Two cases of acute‐onset cystoid macular edema and serous retinal detachment associated with combined use of encorafenib and binimetinib for advanced melanoma: A possible confounding risk for drug intolerance
    Takumi Hasegawa et al, 2023, J Cutaneous Imm & Allergy CrossRef
46. Early Optical Coherence Tomography Signs of Erdafitinib-Induced Retinopathy
    Carson W Ercanbrack et al, 2024 CrossRef
47. Endocrine effects of MEK and BRAF inhibitor therapy in paediatric patients: a tertiary centre experience
    Arif Hanafi Bin Jalal et al, 2024, J Neurooncol CrossRef
48. Aquaporin‑1 regulates microglial polarization and inflammatory response in traumatic brain injury
    Yixuan Ma et al, 2025, Int J Mol Med CrossRef